Your request to link to rcsb for EGFR(L858R)
- 1IVO: crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. (10.1016/S0092-8674(02)00963-7 )
- 1M14: tyrosine kinase domain from epidermal growth factor receptor (10.1074/JBC.M207135200 )
- 1M17: epidermal growth factor receptor tyrosine kinase domain with 4-anilinoquinazoline inhibitor erlotinib (10.1074/JBC.M207135200 )
- 1MOX: crystal structure of human epidermal growth factor receptor (residues 1-501) in complex with tgf-alpha (10.1016/S0092-8674(02)00940-6 )
- 1NQL: structure of the extracellular domain of human epidermal growth factor (egf) receptor in an inactive (low ph) complex with egf. (10.1016/S1097-2765(03)00047-9 )
- 1XKK: egfr kinase domain complexed with a quinazoline inhibitor- gw572016 (10.1158/0008-5472.CAN-04-1168 )
- 1YY9: structure of the extracellular domain of the epidermal growth factor receptor in complex with the fab fragment of cetuximab/erbitux/imc- c225 (10.1016/J.CCR.2005.03.003 )
- 1Z9I: a structural model for the membrane-bound form of the juxtamembrane domain of the epidermal growth factor receptor (10.1074/JBC.M502698200 )
- 2EB2: crystal structure of mutated egfr kinase domain (g719s) (10.1038/ONC.2012.21 )
- 2EB3: crystal structure of mutated egfr kinase domain (l858r) in complex with amppnp (10.1038/ONC.2012.21 )
- 2GS2: crystal structure of the active egfr kinase domain (10.1016/J.CELL.2006.05.013 )
- 2GS6: crystal structure of the active egfr kinase domain in complex with an atp analog-peptide conjugate (10.1016/J.CELL.2006.05.013 )
- 2GS7: crystal structure of the inactive egfr kinase domain in complex with amp-pnp (10.1016/J.CELL.2006.05.013 )
- 2ITN: crystal structure of egfr kinase domain g719s mutation in complex with amp-pnp (10.1016/J.CCR.2006.12.017 )
- 2ITO: crystal structure of egfr kinase domain g719s mutation in complex with iressa (10.1016/J.CCR.2006.12.017 )
- 2ITP: crystal structure of egfr kinase domain g719s mutation in complex with aee788 (10.1016/J.CCR.2006.12.017 )
- 2ITQ: crystal structure of egfr kinase domain g719s mutation in complex with afn941 (10.1016/J.CCR.2006.12.017 )
- 2ITT: crystal structure of egfr kinase domain l858r mutation in complex with aee788 (10.1016/J.CCR.2006.12.017 )
- 2ITU: crystal structure of egfr kinase domain l858r mutation in complex with afn941 (10.1016/J.CCR.2006.12.017 )
- 2ITV: crystal structure of egfr kinase domain l858r mutation in complex with amp-pnp (10.1016/J.CCR.2006.12.017 )
- 2ITW: crystal structure of egfr kinase domain in complex with afn941 (10.1016/J.CCR.2006.12.017 )
- 2ITX: crystal structure of egfr kinase domain in complex with amp- pnp (10.1016/J.CCR.2006.12.017 )
- 2ITY: crystal structure of egfr kinase domain in complex with iressa (10.1016/J.CCR.2006.12.017 )
- 2ITZ: crystal structure of egfr kinase domain l858r mutation in complex with iressa (10.1016/J.CCR.2006.12.017 )
- 2J5E: crystal structure of egfr kinase domain in complex with an irreversible inhibitor 13-jab (10.1038/NCHEMBIO866 )
- 2J5F: crystal structure of egfr kinase domain in complex with an irreversible inhibitor 34-jab (10.1038/NCHEMBIO866 )
- 2J6M: crystal structure of egfr kinase domain in complex with aee788 (10.1016/J.CCR.2006.12.017 )
- 2JIT: crystal structure of egfr kinase domain t790m mutation (10.1073/PNAS.0709662105 )
- 2JIU: crystal structure of egfr kinase domain t790m mutation in complex with aee788 (10.1073/PNAS.0709662105 )
- 2JIV: crystal structure of egfr kinase domain t790m mutation in compex with hki-272 (10.1073/PNAS.0709662105 )
- 2M20: egfr transmembrane - juxtamembrane (tm-jm) segment in bicelles: md guided nmr refined structure. (10.1016/J.CELL.2012.12.032 )
- 2N5S: spatial structure of egfr transmembrane and juxtamembrane domains in dpc micelles (10.1021/ACS.BIOCHEM.5B00851 )
- 2RF9: crystal structure of the complex between the egfr kinase domain and a mig6 peptide (10.1038/NATURE05998 )
- 2RFD: crystal structure of the complex between the egfr kinase domain and a mig6 peptide (10.1038/NATURE05998 )
- 2RFE: crystal structure of the complex between the egfr kinase domain and a mig6 peptide (10.1038/NATURE05998 )
- 2RGP: structure of egfr in complex with hydrazone, a potent dual inhibitor (10.1016/J.BMCL.2008.07.020 )
- 3B2U: crystal structure of isolated domain iii of the extracellular region of the epidermal growth factor receptor in complex with the fab fragment of imc-11f8 (10.1016/J.STR.2007.11.009 )
- 3B2V: crystal structure of the extracellular region of the epidermal growth factor receptor in complex with the fab fragment of imc-11f8 (10.1016/J.STR.2007.11.009 )
- 3BEL: x-ray structure of egfr in complex with oxime inhibitor (10.1016/J.BMCL.2008.05.024 )
- 3C09: crystal structure the fab fragment of matuzumab (fab72000) in complex with domain iii of the extracellular region of egfr (10.1016/J.CCR.2008.02.019 )
- 3GOP: crystal structure of the egf receptor juxtamembrane and kinase domains (10.1016/J.MOLCEL.2009.04.034 )
- 3GT8: crystal structure of the inactive egfr kinase domain in complex with amp-pnp 04-aug-09 3gt8 1 title (10.1016/J.CELL.2009.04.025 )
- 3IKA: crystal structure of egfr 696-1022 t790m mutant covalently binding to wz4002 (10.1038/NATURE08622 )
- 3LZB: egfr kinase domain complexed with an imidazo[2,1-b]thiazole inhibitor (10.1016/J.BMCL.2010.03.015 )
- 3NJP: the extracellular and transmembrane domain interfaces in epidermal growth factor receptor signaling (10.1128/MCB.00742-10 )
- 3P0Y: anti-egfr/her3 fab dl11 in complex with domain iii of egfr extracellular region (10.1016/J.CCR.2011.09.003 )
- 3POZ: egfr kinase domain complexed with tak-285 (10.1074/JBC.M110.206193 )
- 3QWQ: crystal structure of the extracellular domain of the epidermal growth factor receptor in complex with an adnectin (10.1016/J.STR.2011.11.016 )
- 3UG1: crystal structure of the mutated egfr kinase domain (g719s/t790m) in the apo form (10.1038/ONC.2012.21 )
- 3UG2: crystal structure of the mutated egfr kinase domain (g719s/t790m) in complex with gefitinib (10.1038/ONC.2012.21 )
- 3VJN: crystal structure of the mutated egfr kinase domain (g719s/t790m) in complex with amppnp. (10.1038/ONC.2012.21 )
- 3VJO: crystal structure of the wild-type egfr kinase domain in complex with amppnp. (10.1038/ONC.2012.21 )
- 3W2O: egfr kinase domain t790m/l858r mutant with tak-285 (10.1021/ML300327Z )
- 3W2P: egfr kinase domain t790m/l858r mutant with compound 2 (10.1021/ML300327Z )
- 3W2Q: egfr kinase domain t790m/l858r mutant with hki-272 (10.1021/ML300327Z )
- 3W2R: egfr kinase domain t790m/l858r mutant with compound 4 (10.1021/ML300327Z )
- 3W2S: egfr kinase domain with compound4 (10.1021/ML300327Z )
- 3W32: egfr kinase domain complexed with compound 20a (10.1016/J.BMC.2013.02.014 )
- 3W33: egfr kinase domain complexed with compound 19b (10.1016/J.BMC.2013.02.014 )
- 4G5J: crystal structure of egfr kinase in complex with bibw2992 (10.1124/JPET.112.197756 )
- 4G5P: crystal structure of egfr kinase t790m in complex with bibw2992 (10.1124/JPET.112.197756 )
- 4HJO: crystal structure of the inactive egfr tyrosine kinase domain with erlotinib (10.1042/BJ20121513 )
- 4I1Z: crystal structure of the monomeric (v948r) form of the gefitinib/erlotinib resistant egfr kinase domain l858r+t790m (10.1016/J.STR.2012.11.014 )
- 4I20: crystal structure of monomeric (v948r) primary oncogenic mutant l858r egfr kinase domain (10.1016/J.STR.2012.11.014 )
- 4I21: crystal structure of l858r + t790m egfr kinase domain in complex with mig6 peptide (10.1016/J.STR.2012.11.014 )
- 4I22: structure of the monomeric (v948r)gefitinib/erlotinib resistant double mutant (l858r+t790m) egfr kinase domain co-crystallized with gefitinib (10.1016/J.STR.2012.11.014 )
- 4I23: crystal structure of the wild-type egfr kinase domain in complex with dacomitinib (soaked) (10.1016/J.STR.2012.11.014 )
- 4I24: structure of t790m egfr kinase domain co-crystallized with dacomitinib (10.1016/J.STR.2012.11.014 )
- 4JQ7: crystal structure of egfr kinase domain in complex with compound 2a (10.1021/JM400072P )
- 4JQ8: crystal structure of egfr kinase domain in complex with compound 4b (10.1021/JM400072P )
- 4JR3: crystal structure of egfr kinase domain in complex with compound 3g (10.1021/JM400072P )
- 4JRV: crystal structure of egfr kinase domain in complex with compound 4c (10.1021/JM400072P )
- 4KRL: nanobody/vhh domain 7d12 in complex with domain iii of the extracellular region of egfr, ph 6.0 (10.1016/J.STR.2013.05.008 )
- 4KRM: nanobody/vhh domain 7d12 in complex with domain iii of the extracellular region of egfr, ph 3.5 (10.1016/J.STR.2013.05.008 )
- 4KRO: nanobody/vhh domain ega1 in complex with the extracellular region of egfr (10.1016/J.STR.2013.05.008 )
- 4KRP: nanobody/vhh domain 9g8 in complex with the extracellular region of egfr (10.1016/J.STR.2013.05.008 )
- 4LI5: egfr-k in complex with n-[3-[[5-chloro-4-(1h-indol-3-yl)pyrimidin-2- yl]amino]-4-methoxy-phenyl] prop-2-enamide (10.1021/JM400822Z )
- 4LL0: egfr l858r/t790m in complex with pd168393 (10.1073/PNAS.1220050110 )
- 4LQM: egfr l858r in complex with pd168393 (10.1126/SCITRANSLMED.3007205 )
- 4LRM: egfr d770_n771insnpg in complex with pd168393 (10.1126/SCITRANSLMED.3007205 )
- 4R3P: crystal structures of egfr in complex with mig6 (10.1038/NSMB.3074 )
- 4R3R: crystal structures of egfr in complex with mig6 (10.1038/NSMB.3074 )
- 4R5S: crystal structure of egfr 696-1022 l858r in complex with fiin-3 (10.1073/PNAS.1403438111 )
- 4RIW: crystal structure of an egfr/her3 kinase domain heterodimer (10.1126/SCISIGNAL.2005786 )
- 4RIX: crystal structure of an egfr/her3 kinase domain heterodimer containing the cancer-associated her3-q790r mutation (10.1126/SCISIGNAL.2005786 )
- 4RIY: crystal structure of an egfr/her3 kinase domain heterodimer containing the cancer-associated her3-e909g mutation (10.1126/SCISIGNAL.2005786 )
- 4RJ4: egfr kinase (t790m/l858r) with inhibitor compound 6 (10.1021/JM501578N )
- 4RJ5: egfr kinase (t790m/l858r) with inhibitor compound 5 (10.1021/JM501578N )
- 4RJ6: egfr kinase (t790m/l858r) with inhibitor compound 4 (10.1021/JM501578N )
- 4RJ7: egfr kinase (t790m/l858r) with inhibitor compound 1 (10.1021/JM501578N )
- 4RJ8: egfr kinase (t790m/l858r) with inhibitor compound 8 (10.1021/JM501578N )
- 4TKS: native-sad phasing for human egfr kinase domain. (10.1107/S1399004714013376 )
- 4UIP: the complex structure of extracellular domain of egfr with repebody (rac1). (10.1002/ANIE.201505964 )
- 4UV7: the complex structure of extracellular domain of egfr and gc1118a 21-oct-15 4uv7 1 title (10.1158/1535-7163.MCT-15-0679 )
- 4WD5: crystal structure of egfr 696-1022 t790m in complex with ql-x138
- 4WKQ: 1.85 angstrom structure of egfr kinase domain with gefitinib
- 4WRG: 1.9 angstrom structure of egfr kinase domain
- 4ZAU: azd9291 complex with wild type egfr (10.1016/J.JSB.2015.10.018 )
- 4ZJV: crystal structure of egfr kinase domain in complex with mitogen- inducible gene 6 protein (10.1038/NSMB.3074 )
- 4ZSE: crystal structure of egfr 696-1022 t790m/v948r, crystal form ii
- 5C8K: egfr kinase domain mutant "tmlr" with compound 1 (10.1021/ACS.JMEDCHEM.5B01412 )
- 5C8M: egfr kinase domain mutant "tmlr" with compound 17 (10.1021/ACS.JMEDCHEM.5B01412 )
- 5C8N: egfr kinase domain mutant "tmlr" with compound 23 (10.1021/ACS.JMEDCHEM.5B01412 )
- 5CAL: egfr kinase domain mutant "tmlr" with compound 24 (10.1021/ACS.JMEDCHEM.5B01412 )
- 5CAN: egfr kinase domain mutant "tmlr" with compound 27 (10.1021/ACS.JMEDCHEM.5B01412 )
- 5CAO: egfr kinase domain mutant "tmlr" with compound 29 (10.1021/ACS.JMEDCHEM.5B01412 )
- 5CAP: egfr kinase domain mutant "tmlr" with compound 30 (10.1021/ACS.JMEDCHEM.5B01412 )
- 5CAQ: egfr kinase domain mutant "tmlr" with compound 33 (10.1021/ACS.JMEDCHEM.5B01412 )
- 5CAS: egfr kinase domain mutant "tmlr" with compound 41a (10.1021/ACS.JMEDCHEM.5B01412 )
- 5CAU: egfr kinase domain mutant "tmlr" with compound 41b (10.1021/ACS.JMEDCHEM.5B01412 )
- 5CAV: egfr kinase domain with compound 41a (10.1021/ACS.JMEDCHEM.5B01412 )
- 5CNN: crystal structure of the egfr kinase domain mutant i682q (10.1128/MCB.00248-15 )
- 5CNO: crystal structure of the egfr kinase domain mutant v924r (10.1128/MCB.00248-15 )
- 5CZH: egfr l858r mutant in complex with an optimal peptide substrate (10.1038/NSMB.3117 )
- 5CZI: egfr l858r mutant in complex with a shc peptide substrate (10.1038/NSMB.3117 )
- 5D41: egfr kinase domain in complex with mutant selective allosteric inhibitor (10.1038/NATURE17960 )
- 5EDP: egfr kinase (t790m/l858r) apo (10.1016/J.BMCL.2015.11.078 )
- 5EDQ: egfr kinase (t790m/l858r) with inhibitor compound 15: ~{n}-(7- chloranyl-1~{h}-indazol-3-yl)-7,7-dimethyl-2-(1~{h}-pyrazol-4-yl)- 5~{h}-furo[3,4-d]pyrimidin-4-amine (10.1016/J.BMCL.2015.11.078 )
- 5EDR: egfr kinase (t790m/l858r) with inhibitor compound 27: ~{n}-(1~{h}- indazol-3-yl)-7,7-dimethyl-2-(2-methylpyrazol-3-yl)-5~{h}-furo[3,4- d]pyrimidin-4-amine (10.1016/J.BMCL.2015.11.078 )
- 5EM5: egfr kinase domain mutant "tmlr" with pyridone compound 2: 4-[2-(4- chlorophenyl)ethylamino]-~{n}-[4-(4-methylpiperazin-1-yl)phenyl]-2- oxidanylidene-1~{h}-pyridine-3-carboxamide (10.1021/ACSMEDCHEMLETT.5B00428 )
- 5EM6: egfr kinase domain mutant "tmlr" with pyridone compound 19: 4-[(2- azanylpyrimidin-4-yl)amino]-~{n}-[4-(4-methylpiperazin-1-yl)phenyl]- 2-oxidanylidene-1~{h}-pyridine-3-carboxamide (10.1021/ACSMEDCHEMLETT.5B00428 )
- 5EM7: egfr kinase domain mutant "tmlr" with pyridone compound 13: 4-[(2- methoxyphenyl)amino]-~{n}-[4-(4-methylpiperazin-1-yl)phenyl]-2- oxidanylidene-1~{h}-pyridine-3-carboxamide (10.1021/ACSMEDCHEMLETT.5B00428 )
- 5EM8: egfr kinase domain with pyridone compound 13: 4-[(2-methoxyphenyl) amino]-~{n}-[4-(4-methylpiperazin-1-yl)phenyl]-2-oxidanylidene-1~{h}- pyridine-3-carboxamide (10.1021/ACSMEDCHEMLETT.5B00428 )
- 5FED: egfr kinase domain in complex with a covalent aminobenzimidazole inhibitor. (10.1021/ACS.JMEDCHEM.5B01985 )
- 5FEE: egfr kinase domain t790m mutant in complex with a covalent aminobenzimidazole inhibitor. (10.1021/ACS.JMEDCHEM.5B01985 )
- 5FEQ: egfr kinase domain in complex with a covalent aminobenzimidazole (10.1021/ACS.JMEDCHEM.5B01985 )
- 5GMP: crystal structure of egfr 696-1022 t790m in complex with xtf-262 (10.1016/J.EJMECH.2016.12.006 )
- 5GNK: crystal structure of egfr 696-988 t790m in complex with lxx-6-34 (10.1021/ACS.JMEDCHEM.6B01907 )
- 5GTY: crystal structure of egfr 696-1022 t790m in complex with lxx-6-26 (10.18632/ONCOTARGET.15443 )
- 5GTZ: crystal structure of egfr 696-1022 t790m in complex with jts-1-39
- 5HCX: egfr kinase domain mutant "tmlr" with azabenzimidazole compound 7 (10.1021/ACS.JMEDCHEM.6B00995 )
- 5HCY: egfr kinase domain mutant "tmlr" with 3-carboxamide azaindole compound 13 (10.1021/ACS.JMEDCHEM.6B00995 )
- 5HCZ: egfr kinase domain mutant "tmlr" with 3-azetidinyl azaindazole compound 21 (10.1021/ACS.JMEDCHEM.6B00995 )
- 5HG5: egfr (l858r, t790m, v948r) in complex with n-{3-[(2-{[4-(4- methylpiperazin-1-yl)phenyl]amino}-7h-pyrrolo[2,3-d]pyrimidin-4-yl) oxy]phenyl}prop-2-enamide (10.1021/ACS.JMEDCHEM.5B01633 )
- 5HG7: egfr (l858r, t790m, v948r) in complex with 1-{(3r,4r)-3-[5-chloro-2- (1-methyl-1h-pyrazol-4-ylamino)-7h-pyrrolo[2,3-d]pyrimidin-4- yloxymethyl]-4-methoxy-pyrrolidin-1-yl}propenone (pf-06459988) (10.1021/ACS.JMEDCHEM.5B01633 )
- 5HG8: egfr (l858r, t790m, v948r) in complex with n-[3-({2-[(1-methyl-1h- pyrazol-4-yl)amino]-7h-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)phenyl]prop- 2-enamide (10.1021/ACS.JMEDCHEM.5B01633 )
- 5HG9: egfr (l858r, t790m, v948r) in complex with 1-[(3r,4r)-3-[({2-[(1- methyl-1h-pyrazol-4-yl)amino]-7h-pyrrolo[2,3-d]pyrimidin-4-yl}oxy) methyl]-4-(trifluoromethyl)pyrrolidin-1-yl]prop-2-en-1-one (10.1021/ACS.JMEDCHEM.5B01633 )
- 5HIB: egfr kinase domain mutant "tmlr" with a pyrazolopyrimidine inhibitor (10.1016/J.CCELL.2016.02.010 )
- 5HIC: egfr kinase domain mutant "tmlr" with a imidazopyridinyl- aminopyrimidine inhibitor (10.1016/J.CCELL.2016.02.010 )
- 5J9Y: egfr-t790m in complex with pyrazolopyrimidine inhibitor 1b (10.1002/ANIE.201605011 )
- 5J9Z: egfr-t790m in complex with pyrazolopyrimidine inhibitor 1a (10.1002/ANIE.201605011 )
- 5JEB: crystal structure of egfr tyrosine kinase domain with novel inhibitor of active state of her2 (10.1038/NCHEMBIO.2171 )
- 5SX4: crystal structure of panitumumab in complex with epidermal growth factor receptor domain 3. (10.1371/JOURNAL.PONE.0163366 )
- 5SX5: crystal structure of panitumumab in complex with epidermal growth factor receptor domain 3 mutant s468r. (10.1371/JOURNAL.PONE.0163366 )
- 5U8L: crystal structure of egfr kinase domain in complex with a sulfonyl fluoride probe xo44 (10.1021/JACS.6B08536 )
- 5UG8: crystal structure of the egfr kinase domain (l858r, t790m, v948r) in complex with a covalent inhibitor n-[(3r,4r)-4-fluoro-1-{6-[(1- methyl-1h-pyrazol-4-yl)amino]-9-(propan-2-yl)-9h-purin-2- yl}pyrrolidin-3-yl]propanamide (10.1021/ACS.JMEDCHEM.6B01894 )
- 5UG9: crystal structure of the egfr kinase domain (l858r, t790m, v948r) in complex with a covalent inhibitor n-[(3r,4r)-4-fluoro-1-{6-[(3- methoxy-1-methyl-1h-pyrazol-4-yl)amino]-9-(propan-2-yl)-9h-purin-2- yl}pyrrolidin-3-yl]propanamide (10.1021/ACS.JMEDCHEM.6B01894 )
- 5UGA: crystal structure of the egfr kinase domain (l858r, t790m, v948r) in complex with 4-(4-{[2-{[(3s)-1-acetylpyrrolidin-3-yl]amino}-9- (propan-2-yl)-9h-purin-6-yl]amino}phenyl)-1-methylpiperazin-1-ium (10.1021/ACS.JMEDCHEM.6B01894 )
- 5UGB: crystal structure of the egfr kinase domain in complex with 4-(4-{[2- {[(3s)-1-acetylpyrrolidin-3-yl]amino}-9-(propan-2-yl)-9h-purin-6- yl]amino}phenyl)-1-methylpiperazin-1-ium (10.1021/ACS.JMEDCHEM.6B01894 )
- 5UGC: crystal structure of the egfr kinase domain (l858r, t790m, v948r) in complex with a covalent inhibitor n-[(3r,4r)-4-fluoro-1-{6-[(3- methoxy-1-methyl-1h-pyrazol-4-yl)amino]-9-methyl-9h-purin-2- yl}pyrrolidin-3-yl]propanamide (10.1021/ACS.JMEDCHEM.6B01894 )
- 5UWD: crystal structure of egfr kinase domain (l858r, t790m, v948r) in complex with the covalent inhibitor co-1686 (10.1016/J.CHEMBIOL.2017.08.017 )
- 5WB7: crystal structure of the epidermal growth factor receptor extracellular region in complex with epiregulin (10.1016/J.CELL.2017.09.017 )
- 5WB8: crystal structure of the epidermal growth factor receptor extracellular region in complex with epigen (10.1016/J.CELL.2017.09.017 )
- 5X26: crystal structure of egfr 696-1022 l858r in complex with sklb(3) (10.18632/ONCOTARGET.24113 )
- 5X27: crystal structure of egfr 696-1022 l858r in complex with sklb(5) (10.18632/ONCOTARGET.24113 )
- 5X28: crystal structure of egfr 696-1022 l858r in complex with sklb(6) (10.18632/ONCOTARGET.24113 )
- 5X2A: crystal structure of egfr 696-1022 t790m/v948r in complex with sklb(3) (10.18632/ONCOTARGET.24113 )
- 5X2C: crystal structure of egfr 696-1022 t790m/v948r in complex with sklb(5) (10.18632/ONCOTARGET.24113 )
- 5X2F: crystal structure of egfr 696-1022 t790m/v948r in complex with sklb(6) (10.18632/ONCOTARGET.24113 )
- 5X2K: crystal structure of egfr 696-1022 t790m in complex with wz4003 (10.18632/ONCOTARGET.24113 )
- 5XDK: crystal structure of egfr 696-1022 t790m in complex with co-1686 (10.18632/ONCOTARGET.18588 )
- 5XDL: crystal structure of egfr 696-1022 l858r in complex with co-1686 (10.18632/ONCOTARGET.18588 )
- 5XGM: crystal structure of egfr 696-1022 t790m in complex with go6976 (10.1016/J.BBRC.2017.04.138 )
- 5XGN: crystal structure of egfr 696-1022 t790m/c797s in complex with go6976 (10.1016/J.BBRC.2017.04.138 )
- 5XWD: crystal structure of the complex of 059-152-fv and egfr-ecd (10.1371/JOURNAL.PONE.0193158 )
- 5Y25: egfr kinase domain mutant (t790m/l858r) with covalent ligand ns-062 (10.1038/S41589-018-0204-3 )
- 5Y9T: crystal structure of egfr t790m mutant in complex with naquotinib (10.1158/1535-7163.MCT-17-1033 )
- 5YU9: crystal structure of egfr 696-1022 t790m in complex with ibrutinib (10.18632/ONCOTARGET.11951 )
- 5ZTO: crystal structure of egfr 696-1022 t790m/c797s in complex with d3003
- 5ZWJ: crystal structure of egfr 675-1022 t790m/c797s/v948r in complex with eai045 (10.1016/J.BBRC.2018.05.154 )
- 6ARU: structure of cetuximab fab mutant in complex with egfr extracellular domain
- 6B3S: crystal structure of the fab fragment of necitumumab (fab11f8) in complex with domain iii from a cetuximab resistant variant of egfr (segfrd3-s468r) (10.1158/1535-7163.MCT-17-0575 )
- 6D8E: discovery of a highly potent and broadly effective egfr and her2 exon 20 insertion mutant inhibitor (10.1002/ANIE.201805187 )
- 6DUK: egfr with an allosteric inhibitor (10.1158/2159-8290.CD-18-0903 )
- 6JRJ: the structure of co-crystals of 8r-b-egfr t790m/c797s complex (10.1021/ACS.JMEDCHEM.9B00576 )
- 6JRK: the structure of co-crystals of 8r-b-egfr wt complex (10.1021/ACS.JMEDCHEM.9B00576 )
- 6JRX: egfr t790m/c797s in complex with compound 6i (10.1021/ACS.JMEDCHEM.9B00664 )
- 6JWL: crystal structure of egfr 696-1022 l858r in complex with azd9291 (10.1021/ACS.JMEDCHEM.0C00891 )
- 6JX0: crystal structure of egfr 696-1022 t790m in complex with azd9291 prepared by co-crystallization (10.1021/ACS.JMEDCHEM.0C00891 )
- 6JX4: crystal structure of egfr 696-1022 t790m in complex with azd9291 prepared by soaking (10.1021/ACS.JMEDCHEM.0C00891 )
- 6JXT: crystal structure of egfr 696-1022 wt in complex with azd9291 prepared by cocrystallization (10.1021/ACS.JMEDCHEM.0C00891 )
- 6JZ0: crystal structure of egfr kinase domain in complex with compound 78 (10.1021/ACS.JMEDCHEM.9B00722 )
- 6LUB: crystal structure of egfr(l858r/t790m/c797s) in complex with ch7233163 (10.1158/1535-7163.MCT-20-0229 )
- 6LUD: crystal structure of egfr(l858r/t790m/c797s) in complex with osimertinib (10.1158/1535-7163.MCT-20-0229 )
- 6P1D: crystal structure of egfr with mutant-selective dihydrodibenzodiazepinone allosteric inhibitor (10.1021/ACSMEDCHEMLETT.9B00381 )
- 6P1L: crystal structure of egfr in complex with eai045 (10.1021/ACSMEDCHEMLETT.9B00381 )
- 6P8Q: egfr in complex with a dihydrodibenzodiazepinone allosteric inhibitor. (10.1021/ACSMEDCHEMLETT.9B00381 )
- 6S89: crystal structure of egfr-t790m/c797s in complex with covalent pyrrolopyrimidine 19g (10.1039/C9SC03445E )
- 6S8A: crystal structure of egfr-t790m/c797s in complex with covalent pyrrolopyrimidine 19h (10.1039/C9SC03445E )
- 6S9B: egfr-kinase in complex with compound 1 (10.1021/ACS.JMEDCHEM.9B01169 )
- 6S9C: egfr-kinase in complex with compound 5 (10.1021/ACS.JMEDCHEM.9B01169 )
- 6S9D: egfr-kinase in complex with compound 6 (10.1021/ACS.JMEDCHEM.9B01169 )
- 6TFU: crystal structure of egfr t790m/v948r in complex with covalent pyrrolopyrimidine 14d (10.1021/ACS.JMEDCHEM.0C00870 )
- 6TFV: crystal structure of egfr t790m/v948r in complex with covalent pyrrolopyrimidine 18b (10.1021/ACS.JMEDCHEM.0C00870 )
- 6TFW: crystal structure of egfr t790m/v948r in complex with covalent pyrrolopyrimidine 18d (10.1021/ACS.JMEDCHEM.0C00870 )
- 6TFY: crystal structure of egfr t790m/v948r in complex with covalent pyrrolopyrimidine 18c (10.1021/ACS.JMEDCHEM.0C00870 )
- 6TFZ: crystal structure of egfr t790m/v948r in complex with covalent pyrrolopyrimidine 19 (10.1021/ACS.JMEDCHEM.0C00870 )
- 6TG0: crystal structure of egfr t790m/v948r in complex with covalent pyrrolopyrimidine 21a (10.1021/ACS.JMEDCHEM.0C00870 )
- 6TG1: crystal structure of egfr t790m/v948r in complex with covalent pyrrolopyrimidine 21b (10.1021/ACS.JMEDCHEM.0C00870 )
- 6V5N: egfr(t790m/v948r) in complex with ln2084 (10.1021/ACS.JMEDCHEM.0C00200 )
- 6V5P: egfr(t790m/v948r) in complex with ln2725 (10.1021/ACS.JMEDCHEM.0C00200 )
- 6V66: egfr(t790m/v948r) in complex with ln2899 (10.1021/ACS.JMEDCHEM.0C00200 )
- 6V6K: egfr(t790m/v948r) in complex with ln2057 (10.1021/ACS.JMEDCHEM.0C00200 )
- 6V6O: egfr(t790m/v948r) in complex with ln2380 (10.1021/ACS.JMEDCHEM.0C00200 )
- 6VH4: wild type egfr in complex with ln2380 (10.1021/ACS.JMEDCHEM.0C00200 )
- 6VHN: wild type egfr in complex with ln2057 (10.1021/ACS.JMEDCHEM.0C00200 )
- 6VHP: wild type egfr in complex with ln2899 (10.1021/ACS.JMEDCHEM.0C00200 )
- 6WA2: crystal structure of egfr(t790m/v948r) in complex with ln3753
- 6WAK: a crystal structure of egfr(t790m/v948r) in complex with ln3754
- 6WXN: egfr(t790m/v948r) in complex with ln3844
- 6Z4B: crystal structure of egfr-t790m/v948r in complex with osimertinib and eai045 (10.1021/ACSMEDCHEMLETT.0C00472 )
- 6Z4D: crystal structure of egfr-t790m/v948r in complex with mavelertinib and eai001 (10.1021/ACSMEDCHEMLETT.0C00472 )
- 7A2A: crystal structure of egfr-t790m/v948r in complex with spebrutinib and eai001 (10.1021/ACSMEDCHEMLETT.0C00472 )
- 7AEI: studies towards a reversible egfr c797s triple mutant inhibitor series (10.1158/1538-7445.AM2019-4451 )
- 7AEM: studies towards a reversible egfr c797s triple mutant inhibitor series (10.1158/1538-7445.AM2019-4451 )